The worldwide prevalence of obesity has nearly tripled between 1975 and 2016, reaching more than 1.9 billion adults, of which over 650 million were obese.
We are very happy to inform that we have successfully completed the task regarding microencapsulation of Metabolaid, which is part of the INNOPREFAT project, a H2020 SME instrument phase II project. Microencapsulation has been successfully performed using inulin and maltodextrin as encapsulation agents.
Continue reading INNOPREFAT Milestone Reached: Microencapsulation of Metabolaid through Spray Drying with Inulin and Maltodextrin.
Fi Asia 2018 took place at the beginning of this month in Jakarta (Indonesia). According to the organizers, the event keeps on breaking records not only of attendance but also of exhibitors. The health food market continues to grow in Indonesia at an accelerated pace motivated by the growth of the standard of living and the awareness of the population of the importance of prevention rather than cure.
We are happy to announce that a new study with our weight loss product Metabolaid has been recently published.
In this report, our experts Dr. Nuria Caturla and Dr. Jonathan Jones identify the mechanisms of action of the ingredient, as well as the synergisms of its components.
Specifically, Metabolaid was shown, in mice, to increase AMPK expression in the adipose tissue and liver, which acts as a metabolic switch in the cells, activating lipid degradation and inhibiting adipogenesis. Also, the ingredient acts upon the appetite-regulating gut hormones adiponectin and leptin.
These effects resulted in the treated mice, which were on a high-fat diet, to weigh less, present less body fat, improved lipidic and glycemic blood profile, and less proinflammatory markers when compared to control mice on the same diet. A
nother relevant result is that Metabolaid presented similar or better results than Garcinia cambogia, which was used at 2.5 times higher dosage.
In an article from Malaysia local newspaper, 13.3 percent of the population is facing obesity while 38.5 percent are considered overweight. Bad dietary habit is the root cause of this problem. If one is looking closer to a very typical meals options for individual, it is not difficult to understand why.
A recently published study has shown that a slight reduction in daily caloric intake, approximately 15%, can have beneficial effects on one’s lifespan and health.
Two independent news reports, one from the US and one from the UK, published one day apart from each other, have recently caught my interest: the younger populations, including children and millennials/young adults, will have the highest obesity rates in recorded history.
The numbers are appalling. The incidence rate of obesity in children less than 5 years of age is at its highest, with 26% of them being overweight and 15% obese. Once a child is overweight, the majority remain that way throughout the rest of their lives. At 16-19 years of age, 40% are already obese. In the case of the millennials, it is estimated that 70% of them will be overweight before they are 40.
Excess weight has a terrible effect on their health and quality of life. Not only are they more prone to many health conditions such as type 2 diabetes, cardiovascular disease and fatty liver, but also to around 13 types of cancer. And to be at risk of these diseases at such a young age only makes matters worse, as the probability increases as time goes by.
This is a matter of grave concern, and measures must be taken to stall, if not reverse, the incidence rate. It is still not too late, we must take action by increasing awareness, promote healthy eating habits and physical activity. We must do this, for the sake of the future of our children.
Jonathan Jones, PhD
Product Development Manager
The last day January 22nd, an agreement was signed for the clinical trial of the MetabolAid H2020 project, an SME instrument between Monteloeder and the Universidad Católica de Murcia (UCAM).
Yesterday, Monteloeder presented at a press conference at the University Miguel Hernandez in Elche, the distinction granted by the European Commission (project EU_H2020) for the launching and marketing MetabolAid, an ingredient that provides the solution for Metabolic Syndrome.
Monteloeder would like to thank Mr. Marco Cecchetto (Project Adviser European Commission); Magnífico Mr. D. Jesús Tadeo Pastor (Rector of the UMH); Mr. Manuel Jordá (Vice-rector for Investigation and Innovation of the UMH); and Sr. Vicente Micol (Vice-rector for International Relations of the UMH) for assisting to the press conference.
In addition, the owner of a business Monteloeder, Sr. Ignacio Cartagena and Arturo Lizón Ph.D. (CEO of Monteloeder), as representatives of the company.
Moreover, we would like to thank the media support because we had a massive participation of the mass media, which picked the story up:
-Diario Información: Un freno natural contra la obesidad
OVERVIEW OF THE PRESS CONFERENCE